IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)

NCT06940440 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Or Metastatic Merkel Cell Carcinoma

Interventions

DRUG: IFx-Hu2.0
DRUG: Pembrolizumab

Sponsor

TuHURA Biosciences, Inc.